[1. Bedke J, Buse S, Pritsch M, et al. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences // BJU International, 2009; 103(10):1349-1354]Search in Google Scholar
[2. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma // Am J Surg Pathol, 2003; 27:612-624]Search in Google Scholar
[3. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy // Cancer, 2007; 110:543-550]Search in Google Scholar
[4. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? // Cancer, 2010; 116:3378-3388]Search in Google Scholar
[5. de Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer // Eur J Cancer, 2009; 45:765-773]Search in Google Scholar
[6. Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence // J Clin Oncol, 2006; 24(19):3101-3106]Search in Google Scholar
[7. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma // Cancer Res, 1988; 48:7310-7313]Search in Google Scholar
[8. Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941 // J Urol, 2007; 178:1901-1905]Search in Google Scholar
[9. Escudier B, Kataja V; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol, 2010; 21(5):137-139]Search in Google Scholar
[10. European Cancer Observatory (ECO) // eco.iarc.fr]Search in Google Scholar
[11. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma // Oncologist, 2011; 16(2):4-13]Search in Google Scholar
[12. Flanigan RC, Salmon SE, Blumenstain BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer // N Engl J Med, 2001; 345:1655]Search in Google Scholar
[13. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score // J Urol, 2002; 168:2395-2400]Search in Google Scholar
[14. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study // J Clin Oncol, 2009; 27:5794]Search in Google Scholar
[15. Hudes G, Carducci M, Tomczk P, et al. Temsirolimus, interferon alfa, or both for advanced renal‐cell carcinoma // N Engl J Med, 2007; 356, 2271-228110.1056/NEJMoa06683817538086]Search in Google Scholar
[16. Ii mura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score // J Urol, 2009; 181(3):1004-1012]Search in Google Scholar
[17. Is barn H, Karakiewicz PI. Predicting cancer-control outcomes in patients with renal cell carcinoma // Curr Opin Urol, 2009; 19(3):247-257]Search in Google Scholar
[18. Je ldres C, Karakiewicz PI, Suardi N, et al. Conditional survival predictions after nephrectomy for renal cell carcinoma // J Urol, 2009; 182(6):2607-2612]Search in Google Scholar
[19. Je ppesen AN, Jensen HK, Donskov F, et al. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma // Br J Cancer, 2010; 102:867]Search in Google Scholar
[20. Ka volius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma // J Clin Oncol, 1998; 16:2261-2266]Search in Google Scholar
[21. Ki m HL, Belldegrun AS, Freitas DG, et al. A Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis // J Urol, 2003; 170:1742-1746]Search in Google Scholar
[22. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma // J Urol, 2005; 173(5):1496-1501]Search in Google Scholar
[23. Kuti kov A, Egleston BL, et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram // J Clin Oncol, 2010; 28(2):311-317]Search in Google Scholar
[24. Kuti kov A, Smaldone MC, Egleston, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score // Eur Urol, 2011; 60(2):241-248]Search in Google Scholar
[25. Lee CT, Katz J, Fearn PA, et al. Mode of presentation of renal cell carcinoma provides prognostic information // Urol Oncol, 2002; 7:135-140]Search in Google Scholar
[26. Lee LS, Tan MH. Predictive models for the practical management of renal cell carcinoma// Nat Rev Urol, 2012; 9(2):73-84]Search in Google Scholar
[27. Leib ovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials // J Urol, 2005; 174:1759-176328. Ljun gberg B, Cowan NC B, Cowan NC, et al. EAU guidelines on renal cell carcinoma: the 2010 update // Eur Urol, 2010; 58:398-406]Search in Google Scholar
[29. Mano la J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group // Clin Cancer Res, 2011; 17(16):5443-5450]Search in Google Scholar
[30. Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors // Cancer, 2000; 89:604-614]Search in Google Scholar
[31. Motz er RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. Version 2.2012 // J Natl Compr Canc Netw, 2009; 7:618-30]Search in Google Scholar
[32. Motz er RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan - Kettering Cancer Center experience // Clin Cancer Res, 2004; 10:6302-6303]Search in Google Scholar
[33. Motz er RJ, Bacik J, Murphy BA, et al. Interferon- alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma // J Clin Oncol, 2002; 20:289-296]Search in Google Scholar
[34. Motz er RJ, Bukowski RM, Figlin, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma // Cancer, 2008; 113:1552-1558]Search in Google Scholar
[35. Negr ier S, Gomez F, Douillard JY, et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie // World J Urol, 2005; 23:161-165]Search in Google Scholar
[36. Park er AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma // Cancer, 2009; 115:2092-2103]Search in Google Scholar
[37. Sorb ellini M, Kattan MW, Snyder M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma // J Urol, 2005; 173:48-51]Search in Google Scholar
[38. Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review// Eur Urol, 2011; 60(4):644-661]Search in Google Scholar
[39. Tan MH, Choong CV, Chia KS, et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma // Cancer, 2011; 117:5314-5324]Search in Google Scholar
[40. Tang PA, Vickers MM, Heng DY, Heng YC. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far // Hematol Oncol Clin North Am, 2011; 25(4):871-891]Search in Google Scholar
[41. Tapp er H, Klein H, Rubenstein W, et al. Recurrent renal cell carcinoma after 45 years // Clin Imaging, 1997; 21(4):273-275]Search in Google Scholar
[42. Terr one C, Cracco F, Porpiglia F, et al. Reassessing the current TNM lymph node staging for renal cell carcinoma // Eur Urol, 2006; 49(2):324-31.]Search in Google Scholar
[43. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma // World J Urol, 2010; 28(3):319-327]Search in Google Scholar
[44. Wu Y, Fu X, Xiaoli Z, et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis // J Cancer Res Clin Oncol, 2011; 137(5):887-896]Search in Google Scholar
[45. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma // J Clin Oncol, 2002; 20:4559-4566 ]Search in Google Scholar